2019-004791-19: A Phase 1/2 Study of ACN00177 in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency |
|
|
| Not yet recruiting | 1 | 25 | Europe | ACN00177, Solution for injection | Aeglea Biotherapeutics, Inc., Aeglea Biotherapeutics | Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency, Homocystinuria, Body processes [G] - Metabolic Phenomena [G03] | | | | |
